United States Pancreatic Endocrine Tumor Drug Market Report 2018

January 2018 | 97 pages | ID: U0A7A9DE8D0EN
QYResearch

Abstracts

In this report, the United States Pancreatic Endocrine Tumor Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Pancreatic Endocrine Tumor Drug in these regions, from 2013 to 2025 (forecast).

United States Pancreatic Endocrine Tumor Drug market competition by top manufacturers/players, with Pancreatic Endocrine Tumor Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Ipsen S.A.
• Jiangsu Hengrui Medicine Co., Ltd.
• MediaPharma s.r.l.
• Novartis AG
• OXiGENE, Inc.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Buparlisib Hydrochloride
• Dovitinib Lactate
• Fosbretabulin Tromethamine
• Lanreotide Acetate
• MPHE-001B
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Clinic
• Research Center
• Hospital

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Pancreatic Endocrine Tumor Drug Market Report 2018

1 PANCREATIC ENDOCRINE TUMOR DRUG OVERVIEW

1.1 Product Overview and Scope of Pancreatic Endocrine Tumor Drug
1.2 Classification of Pancreatic Endocrine Tumor Drug by Product Category
  1.2.1 United States Pancreatic Endocrine Tumor Drug Market Size (Sales Volume) Comparison by Type (2013-2025)
  1.2.2 United States Pancreatic Endocrine Tumor Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
  1.2.3 Buparlisib Hydrochloride
  1.2.4 Dovitinib Lactate
  1.2.5 Fosbretabulin Tromethamine
  1.2.6 Lanreotide Acetate
  1.2.7 MPHE-001B
  1.2.8 Others
1.3 United States Pancreatic Endocrine Tumor Drug Market by Application/End Users
  1.3.1 United States Pancreatic Endocrine Tumor Drug Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
  1.3.2 Clinic
  1.3.3 Research Center
  1.3.4 Hospital
1.4 United States Pancreatic Endocrine Tumor Drug Market by Region
  1.4.1 United States Pancreatic Endocrine Tumor Drug Market Size (Value) Comparison by Region (2013-2025)
  1.4.2 The West Pancreatic Endocrine Tumor Drug Status and Prospect (2013-2025)
  1.4.3 Southwest Pancreatic Endocrine Tumor Drug Status and Prospect (2013-2025)
  1.4.4 The Middle Atlantic Pancreatic Endocrine Tumor Drug Status and Prospect (2013-2025)
  1.4.5 New England Pancreatic Endocrine Tumor Drug Status and Prospect (2013-2025)
  1.4.6 The South Pancreatic Endocrine Tumor Drug Status and Prospect (2013-2025)
  1.4.7 The Midwest Pancreatic Endocrine Tumor Drug Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Pancreatic Endocrine Tumor Drug (2013-2025)
  1.5.1 United States Pancreatic Endocrine Tumor Drug Sales and Growth Rate (2013-2025)
  1.5.2 United States Pancreatic Endocrine Tumor Drug Revenue and Growth Rate (2013-2025)

2 UNITED STATES PANCREATIC ENDOCRINE TUMOR DRUG MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Pancreatic Endocrine Tumor Drug Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Pancreatic Endocrine Tumor Drug Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Pancreatic Endocrine Tumor Drug Average Price by Players/Suppliers (2013-2018)
2.4 United States Pancreatic Endocrine Tumor Drug Market Competitive Situation and Trends
  2.4.1 United States Pancreatic Endocrine Tumor Drug Market Concentration Rate
  2.4.2 United States Pancreatic Endocrine Tumor Drug Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Pancreatic Endocrine Tumor Drug Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES PANCREATIC ENDOCRINE TUMOR DRUG SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)

3.1 United States Pancreatic Endocrine Tumor Drug Sales and Market Share by Region (2013-2018)
3.2 United States Pancreatic Endocrine Tumor Drug Revenue and Market Share by Region (2013-2018)
3.3 United States Pancreatic Endocrine Tumor Drug Price by Region (2013-2018)

4 UNITED STATES PANCREATIC ENDOCRINE TUMOR DRUG SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)

4.1 United States Pancreatic Endocrine Tumor Drug Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Pancreatic Endocrine Tumor Drug Revenue and Market Share by Type (2013-2018)
4.3 United States Pancreatic Endocrine Tumor Drug Price by Type (2013-2018)
4.4 United States Pancreatic Endocrine Tumor Drug Sales Growth Rate by Type (2013-2018)

5 UNITED STATES PANCREATIC ENDOCRINE TUMOR DRUG SALES (VOLUME) BY APPLICATION (2013-2018)

5.1 United States Pancreatic Endocrine Tumor Drug Sales and Market Share by Application (2013-2018)
5.2 United States Pancreatic Endocrine Tumor Drug Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 UNITED STATES PANCREATIC ENDOCRINE TUMOR DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Ipsen S.A.
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Pancreatic Endocrine Tumor Drug Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.1.4 Main Business/Business Overview
6.2 Jiangsu Hengrui Medicine Co., Ltd.
  6.2.2 Pancreatic Endocrine Tumor Drug Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.2.4 Main Business/Business Overview
6.3 MediaPharma s.r.l.
  6.3.2 Pancreatic Endocrine Tumor Drug Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.3.4 Main Business/Business Overview
6.4 Novartis AG
  6.4.2 Pancreatic Endocrine Tumor Drug Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Novartis AG Pancreatic Endocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.4.4 Main Business/Business Overview
6.5 OXiGENE, Inc.
  6.5.2 Pancreatic Endocrine Tumor Drug Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.5.4 Main Business/Business Overview

7 PANCREATIC ENDOCRINE TUMOR DRUG MANUFACTURING COST ANALYSIS

7.1 Pancreatic Endocrine Tumor Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Pancreatic Endocrine Tumor Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Pancreatic Endocrine Tumor Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Pancreatic Endocrine Tumor Drug Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES PANCREATIC ENDOCRINE TUMOR DRUG MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)

11.1 United States Pancreatic Endocrine Tumor Drug Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Pancreatic Endocrine Tumor Drug Sales Volume Forecast by Type (2018-2025)
11.3 United States Pancreatic Endocrine Tumor Drug Sales Volume Forecast by Application (2018-2025)
11.4 United States Pancreatic Endocrine Tumor Drug Sales Volume Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Pancreatic Endocrine Tumor Drug
Figure United States Pancreatic Endocrine Tumor Drug Market Size (K Pcs) by Type (2013-2025)
Figure United States Pancreatic Endocrine Tumor Drug Sales Volume Market Share by Type (Product Category) in 2017
Figure Buparlisib Hydrochloride Product Picture
Figure Dovitinib Lactate Product Picture
Figure Fosbretabulin Tromethamine Product Picture
Figure Lanreotide Acetate Product Picture
Figure MPHE-001B Product Picture
Figure Others Product Picture
Figure United States Pancreatic Endocrine Tumor Drug Market Size (K Pcs) by Application (2013-2025)
Figure United States Sales Market Share of Pancreatic Endocrine Tumor Drug by Application in 2017
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Research Center Examples
Table Key Downstream Customer in Research Center
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure United States Pancreatic Endocrine Tumor Drug Market Size (Million USD) by Region (2013-2025)
Figure The West Pancreatic Endocrine Tumor Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Pancreatic Endocrine Tumor Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Pancreatic Endocrine Tumor Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Pancreatic Endocrine Tumor Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Pancreatic Endocrine Tumor Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Pancreatic Endocrine Tumor Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Pancreatic Endocrine Tumor Drug Sales (K Pcs) and Growth Rate (2013-2025)
Figure United States Pancreatic Endocrine Tumor Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Pancreatic Endocrine Tumor Drug Market Major Players Product Sales Volume (K Pcs) (2013-2018)
Table United States Pancreatic Endocrine Tumor Drug Sales (K Pcs) of Key Players/Suppliers (2013-2018)
Table United States Pancreatic Endocrine Tumor Drug Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Pancreatic Endocrine Tumor Drug Sales Share by Players/Suppliers
Figure 2017 United States Pancreatic Endocrine Tumor Drug Sales Share by Players/Suppliers
Figure United States Pancreatic Endocrine Tumor Drug Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Pancreatic Endocrine Tumor Drug Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Pancreatic Endocrine Tumor Drug Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Pancreatic Endocrine Tumor Drug Revenue Share by Players/Suppliers
Figure 2017 United States Pancreatic Endocrine Tumor Drug Revenue Share by Players/Suppliers
Table United States Market Pancreatic Endocrine Tumor Drug Average Price (USD/Pcs) of Key Players/Suppliers (2013-2018)
Figure United States Market Pancreatic Endocrine Tumor Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2017
Figure United States Pancreatic Endocrine Tumor Drug Market Share of Top 3 Players/Suppliers
Figure United States Pancreatic Endocrine Tumor Drug Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Pancreatic Endocrine Tumor Drug Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Pancreatic Endocrine Tumor Drug Product Category
Table United States Pancreatic Endocrine Tumor Drug Sales (K Pcs) by Region (2013-2018)
Table United States Pancreatic Endocrine Tumor Drug Sales Share by Region (2013-2018)
Figure United States Pancreatic Endocrine Tumor Drug Sales Share by Region (2013-2018)
Figure United States Pancreatic Endocrine Tumor Drug Sales Market Share by Region in 2017
Table United States Pancreatic Endocrine Tumor Drug Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Pancreatic Endocrine Tumor Drug Revenue Share by Region (2013-2018)
Figure United States Pancreatic Endocrine Tumor Drug Revenue Market Share by Region (2013-2018)
Figure United States Pancreatic Endocrine Tumor Drug Revenue Market Share by Region in 2017
Table United States Pancreatic Endocrine Tumor Drug Price (USD/Pcs) by Region (2013-2018)
Table United States Pancreatic Endocrine Tumor Drug Sales (K Pcs) by Type (2013-2018)
Table United States Pancreatic Endocrine Tumor Drug Sales Share by Type (2013-2018)
Figure United States Pancreatic Endocrine Tumor Drug Sales Share by Type (2013-2018)
Figure United States Pancreatic Endocrine Tumor Drug Sales Market Share by Type in 2017
Table United States Pancreatic Endocrine Tumor Drug Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Pancreatic Endocrine Tumor Drug Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Pancreatic Endocrine Tumor Drug by Type (2013-2018)
Figure Revenue Market Share of Pancreatic Endocrine Tumor Drug by Type in 2017
Table United States Pancreatic Endocrine Tumor Drug Price (USD/Pcs) by Types (2013-2018)
Figure United States Pancreatic Endocrine Tumor Drug Sales Growth Rate by Type (2013-2018)
Table United States Pancreatic Endocrine Tumor Drug Sales (K Pcs) by Application (2013-2018)
Table United States Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2013-2018)
Figure United States Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2013-2018)
Figure United States Pancreatic Endocrine Tumor Drug Sales Market Share by Application in 2017
Table United States Pancreatic Endocrine Tumor Drug Sales Growth Rate by Application (2013-2018)
Figure United States Pancreatic Endocrine Tumor Drug Sales Growth Rate by Application (2013-2018)
Table Ipsen S.A. Basic Information List
Table Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales Growth Rate (2013-2018)
Figure Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales Market Share in United States (2013-2018)
Figure Ipsen S.A. Pancreatic Endocrine Tumor Drug Revenue Market Share in United States (2013-2018)
Table Jiangsu Hengrui Medicine Co., Ltd. Basic Information List
Table Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales Growth Rate (2013-2018)
Figure Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales Market Share in United States (2013-2018)
Figure Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Revenue Market Share in United States (2013-2018)
Table MediaPharma s.r.l. Basic Information List
Table MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales Growth Rate (2013-2018)
Figure MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales Market Share in United States (2013-2018)
Figure MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Revenue Market Share in United States (2013-2018)
Table Novartis AG Basic Information List
Table Novartis AG Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Novartis AG Pancreatic Endocrine Tumor Drug Sales Growth Rate (2013-2018)
Figure Novartis AG Pancreatic Endocrine Tumor Drug Sales Market Share in United States (2013-2018)
Figure Novartis AG Pancreatic Endocrine Tumor Drug Revenue Market Share in United States (2013-2018)
Table OXiGENE, Inc. Basic Information List
Table OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales Growth Rate (2013-2018)
Figure OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales Market Share in United States (2013-2018)
Figure OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Revenue Market Share in United States (2013-2018)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Pancreatic Endocrine Tumor Drug
Figure Manufacturing Process Analysis of Pancreatic Endocrine Tumor Drug
Figure Pancreatic Endocrine Tumor Drug Industrial Chain Analysis
Table Raw Materials Sources of Pancreatic Endocrine Tumor Drug Major Players/Suppliers in 2017
Table Major Buyers of Pancreatic Endocrine Tumor Drug
Table Distributors/Traders List
Figure United States Pancreatic Endocrine Tumor Drug Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure United States Pancreatic Endocrine Tumor Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Pancreatic Endocrine Tumor Drug Price (USD/Pcs) Trend Forecast (2018-2025)
Table United States Pancreatic Endocrine Tumor Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Pancreatic Endocrine Tumor Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Pancreatic Endocrine Tumor Drug Sales Volume (K Pcs) Forecast by Type in 2025
Table United States Pancreatic Endocrine Tumor Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Pancreatic Endocrine Tumor Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Pancreatic Endocrine Tumor Drug Sales Volume (K Pcs) Forecast by Application in 2025
Table United States Pancreatic Endocrine Tumor Drug Sales Volume (K Pcs) Forecast by Region (2018-2025)
Table United States Pancreatic Endocrine Tumor Drug Sales Volume Share Forecast by Region (2018-2025)
Figure United States Pancreatic Endocrine Tumor Drug Sales Volume Share Forecast by Region (2018-2025)
Figure United States Pancreatic Endocrine Tumor Drug Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources